Zobrazeno 1 - 10
of 211
pro vyhledávání: '"N Zilembo"'
Autor:
R Buzzoni, L Biganzoli, E Bajetta, L Celio, A Fornasiero, L Mariani, N Zilembo, M Di Bartolomeo, A Di Leo, G Arcangeli, E Aitini, G Farina, G Schieppati, D Galluzzo, A Martinetti
Publikováno v:
British Journal of Cancer. 71:1111-1114
It has been suggested that tamoxifen may improve the efficacy of medical castration with luteinising hormone-releasing hormone analogues, but very few data have so far been published concerning the clinical and endocrinological activity of this thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac0cce5a3e794ebb2ad2b9682521d041
https://doi.org/10.1038/bjc.1995.215
https://doi.org/10.1038/bjc.1995.215
Autor:
P. Nelli, Enrico Aitini, C. Noberasco, C.P. Lui, L. Beckman, Yoichi Ikeda, Masakuni Noguchi, Sylvie Mazoyer, Ann-Lii Cheng, Masaki Mori, Arnaldo C. Medeiros, Alberto Ravaioli, Franco Desiderio, Franco Frigerio, Junkichi Kim, Gabriele Tancini, Takao Suzuki, Franco Rovelli, A. Bono, Tatsuro Kamakura, Maria Mitzi Brentani, G. Nastasi, Lurdes A. Marques, Massimo Franchi, Fernando Brivio, B. Müller, A. Di Leo, Kun-Huei Yeh, E. Jäger, Hiroshi Nakano, Giovanna Cavazzini, C. Fan, Pier Paolo Fattori, Mitsuharu Earashi, Marina Cazzaniga, U. Stendahl, Flavia Zanaboni, Kazuo Kinoshita, M. Nicolini, F. Gaion, Mikio Makuuchi, Hideaki Nagasaki, Hwei-Fang Tien, Paolo Lissoni, Einar K. Rofstad, Keizo Sugimachi, F. Cappuzzo, E. Bichisao, Maria Aparecida Nagai, Theorickus C. Viljoen, A Tusei, S.K. Kong, N. Zilembo, K.P. Fung, Giuseppina Arcangeli, C.Y. Lee, Haruki Oomori, M. Colleoni, Sandro Barni, N. Stjernberg, Kaoru Kumada, E. Pasquini, Seizo Minagawa, Mauro Moroni, P. Manente, Heidi Lyng, Franco Monti, Casper H. van Aswegen, A. Knuth, Camillo Porta, Maria Enrica Forghieri, Dion J. du Plessis, G. Sgarbossa, O. Klein, Haruo Tateishi, B. Wächter, Jun Sasaki, E. Bajetta, E. Scorbati, Lois M. Mulligan, Itsuo Miyazaki, Masahide Minami, Nicoletta Donadello, Lorenzo Gianni, Kimio Namatame, Antonio Ardizzoia, C. Bartoli, Y.M. Choy, Nobuhiro Koyanagi, U. Braun
Publikováno v:
Oncology. 52:I-VI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::443c498df9bb22a18ba1293f09664cec
https://doi.org/10.1159/000227505
https://doi.org/10.1159/000227505
Publikováno v:
Oncology reports. 1(1)
The role of medical treatment in advanced or metastatic malignant melanoma is still controversial, and there is no standard systemic therapy. Dacarbazine has been the most widely used single drug, despite its response rate range of 10-25%. A number o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d67627b1b34d5fab308f371ba11dd675
https://pubmed.ncbi.nlm.nih.gov/21607311
https://pubmed.ncbi.nlm.nih.gov/21607311
Autor:
A. Contegiacomo, R. Mariani Costantini, R. Muraro, P. Battista, C. Valli, L. Frati, R. Calderopoli, N. Zilembo, I. Falco, G. Petrella, A.R. Bianco
Publikováno v:
Scopus-Elsevier
Twenty-six primary breast carcinomas were studied to evaluate cell proliferation as assessed by thymidine labeling index (TLI), and antigenic phenotype, as defined by immunohistochemistry using eight monoclonal antibodies (MAbs) to tumor-associated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd88441bd6784b59946a7ca0de3825dc
https://doi.org/10.1177/172460089100600304
https://doi.org/10.1177/172460089100600304
Autor:
E, Bajetta, E, Bichisao, S, Artale, L, Celio, L, Ferrari, M, Di Bartolomeo, N, Zilembo, S C, Stani, R, Buzzoni
Publikováno v:
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 44(1)
In oncology there is an increasing interest in neuroendocrine tumors, whose incidence is generally considered low, although in a recent analysis of 5,468 cases there was an increase in the proportion of pulmonary and gastric carcinoids and a decrease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c04416affac26d105dae8258e2e49b5f
https://pubmed.ncbi.nlm.nih.gov/10932606
https://pubmed.ncbi.nlm.nih.gov/10932606
Autor:
Manfred Kaufmann, C Fowst, Stephen E. Jones, Jean-Louis Dugardyn, Robert G. Mennel, N Zilembo, G. Massimini, E. Di Salle, Luc Dirix, L L Miller, A Polli, Alexei Arkhipov, E. Bajetta, Cristina Nasurdi, J. Cervek, G Piscitelli, L E Fein
Publikováno v:
Journal of clinical oncology
PURPOSE: This phase III, double-blind, randomized, multicenter study evaluated the efficacy, pharmacodynamics, and safety of the oral aromatase inactivator exemestane (EXE) versus megestrol acetate (MA) in postmenopausal women with progressive advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f946db17a4f0b2089e920365dae3c13
https://hdl.handle.net/10067/288110151162165141
https://hdl.handle.net/10067/288110151162165141
Autor:
E, Bajetta, N, Zilembo, M, Dowsett, L, Guillevin, A, Di Leo, L, Celio, A, Martinetti, A, Marchianò, P, Pozzi, S, Stani, E, Bichisao
Publikováno v:
European journal of cancer (Oxford, England : 1990). 35(2)
Letrozole is an orally competitive aromatase inhibitor. This double-blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d6f489b80244d3e7205db4b1ae3168b2
https://pubmed.ncbi.nlm.nih.gov/10448261
https://pubmed.ncbi.nlm.nih.gov/10448261
Autor:
E, Bajetta, N, Zilembo, S, Barni, C, Noberasco, A, Martinetti, L, Ferrari, G, Schieppati, R, Buzzoni, A, Jirillo, M, Amichetti, M, D'Aprile, G, Comella, E, Bichisao, G F, Bolelli, A, Attili, E, Bombardieri
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 8(7)
In postmenopausal breast cancer (BC) patients, tamoxifen (TAM) is frequently used in first-line therapy, and for those relapsing under TAM, aromatase inhibitors would be the drug of choice. Formestane, a new aromatase inhibitor, has been demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e1c6c56d29c2bda040d2ae3badae57fd
https://pubmed.ncbi.nlm.nih.gov/9296217
https://pubmed.ncbi.nlm.nih.gov/9296217
Autor:
N Zilembo, C Noberasco, E Bajetta, A Martinetti, L Mariani, S Orefice, R Buzzoni, M Di Bartolomeo, A Di Leo, A Laffranchi, E di Salle
Publikováno v:
British Journal of Cancer
The androstenedione derivative, exemestane (FCE 24304), is a new orally active irreversible aromatase inhibitor. Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate the activity of four low exemestane doses in red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a260d4e944eee900d2f2855765827495
https://pubmed.ncbi.nlm.nih.gov/7547212
https://pubmed.ncbi.nlm.nih.gov/7547212
Autor:
E, Bajetta, N, Zilembo, R, Buzzoni, C, Noberasco, A, Martinetti, L, Ferrari, C, Bartoli, V, Sacchini, A, Attili, P, Lepera
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 5
Aromatase inhibitors are a useful therapeutic option in the management of endocrine-dependent advanced breast cancer. Formestane (Lentaron) is the first irreversible aromatase inhibitor to be extensively investigated. In a phase II study to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3316a3a841989a360917b602d6a0a831
https://pubmed.ncbi.nlm.nih.gov/7873456
https://pubmed.ncbi.nlm.nih.gov/7873456